CERo Therapeutics - CERO Net Assets per Single Share

The colossal scaling potential of universal cell products provides CERo Therapeutics (CERO) with superprofits, as confirmed by the book value per share chart on GURU.Markets, where the -8.58 indicator expresses the state of the metric. Business stability relies on a long-term testing plan regardless of macroeconomics, while a unique phagocytosis mechanism creates powerful patent protection that precludes price wars.

CERO: CERo Therapeutics Net Asset Value per Share 02/21/2024 - 11/08/2025

CERo Therapeutics Holdings, Inc. - analytical breakdowns and key metrics (CERO)

- price and consensus price forecast:

Price Chart CERo Therapeutics Holdings Inc.|CERO - Fair Value Consensus

- market capitalization data:

Market Value CERo Therapeutics Holdings|CERO - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share CERo Therapeutics|CERO - Total Stockholders' Equity|Market Value to Book Value Ratio cero.bio|CERO - Total Business Assets

- debt and liquidity data:

Total Debt to Capital CERo Therapeutics|CERO - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity CERo Therapeutics Holdings Inc.|CERO - Company Cumulative Debt|Debt to Book Capitalization Ratio CERo Therapeutics Holdings

Fundamental company valuation:CERO - cero.bio

Flagship merchandise of CERo Therapeutics Holdings Inc.

Within a biotech sector characterized by high R&D barriers and T-cell engineering patents, CERo Therapeutics (CERO) represents an attractive M&A target. By analyzing the book value per common share, an investor assesses the ratio of net assets to the number of shares, which determines the business's liquidation base and protects against overpaying for unjustified goodwill, thereby confirming the company's financial stability.

Competitor analysis for CERo Therapeutics